Related Experiment Video
Updated: Jun 13, 2026

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice
Published on: June 2, 2022
Gut microbiota-derived indole-3-propionic acid alleviates endoplasmic reticulum stress by regulating FMO2 in MASLD
Yue Luo1, Yuefeng Zhang1, Qian Zhang1
1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China.
Background:
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global health challenge for which there are currently no approved drugs. Indole-3-propionic acid (IPA), as one of the primary metabolites of gut microbiota, can influence the development of liver diseases through the gut-liver axis, but how it contributes to liver diseases remains unclear. The present study was conducted to explore the possible molecular mechanisms of IPA in the development of MASLD.
Methods:
Metabolomic analysis compared serum and fecal metabolite profiles between MASLD and normal mice. The effects of microbial metabolite IPA on MASLD were evaluated through the utilization of a mouse model and cell models. Transcriptome data analysis was used, and further validation was conducted through flow cytometry, western blotting, RNA interference, and immunoprecipitation.
Results:
Serum and fecal IPA levels in high-fat diet-fed mice were significantly decreased compared with those of normal chow diet-fed mice. IPA supplementation reduced hepatic lipid accumulation and alleviated insulin resistance, liver damage, and steatosis development in high-fat diet-fed mice, while gut microbiota dysbiosis was restored. Mechanistic analysis suggested that IPA promoted FMO2 expression, enhancing the interaction between FMO2 and protein kinase R-like endoplasmic reticulum kinase (PERK) and inhibiting the PERK/eIF2α/ATF4/CHOP signaling cascade, then mitigating endoplasmic reticulum (ER) stress, such as reducing hepatocyte apoptosis and reactive oxygen species levels, ultimately improving MASLD.
Conclusions:
IPA can promote the expression of FMO2, which binds to PERK within the ER of hepatocytes. This binding process inhibits the phosphorylation of PERK, thereby affecting PERK-mediated ER stress, and subsequently leading to a reduction in hepatocyte apoptosis and oxidation. This study puts forward the IPA/FMO2/PERK axis as a potential therapeutic target in ER stress for MASLD.
Insights
Indole-3-propionic acid (IPA) supplementation improves metabolic dysfunction-associated steatotic liver disease (MASLD) by restoring gut microbiota and reducing liver fat. IPA targets the FMO2/PERK pathway to alleviate endoplasmic reticulum stress.
Area of Science:
- Hepatology
- Microbiome Research
- Metabolic Diseases
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern with no approved treatments.
- The role of gut microbiota metabolites, like Indole-3-propionic acid (IPA), in MASLD pathogenesis is not fully understood.
- Investigating IPA's molecular mechanisms is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying the effects of Indole-3-propionic acid (IPA) in the development of metabolic dysfunction-associated steatotic liver disease (MASLD).
- To evaluate the therapeutic potential of IPA in a mouse model of MASLD.
Main Methods:
- Comparative metabolomic analysis of serum and fecal samples from MASLD and normal mice.
- In vivo studies using a MASLD mouse model and in vitro studies using cell models to assess IPA's effects.
- Transcriptome analysis, flow cytometry, western blotting, RNA interference, and immunoprecipitation for mechanistic validation.
Main Results:
- Serum and fecal IPA levels were significantly reduced in MASLD mice.
- IPA supplementation ameliorated hepatic lipid accumulation, insulin resistance, liver damage, and steatosis, while restoring gut microbiota balance.
- Mechanistically, IPA promotes FMO2 expression, which inhibits the PERK/eIF2α/ATF4/CHOP pathway, reducing endoplasmic reticulum stress, hepatocyte apoptosis, and reactive oxygen species.
Conclusions:
- IPA enhances FMO2 expression, leading to FMO2-PERK binding in hepatocytes, inhibiting PERK phosphorylation and subsequent ER stress.
- This mechanism reduces hepatocyte apoptosis and oxidative stress, offering a novel therapeutic approach for MASLD.
- The IPA/FMO2/PERK axis represents a potential therapeutic target for managing ER stress in MASLD.
Related Concept Videos
Microbiota Modulation by Antibiotics
Stringent Response in E. coli
Microbiota of the Large Intestine
Functions of the Gut Microbiota
Dysbiosis of the Gut Microbiota
Regulation of the Unfolded Protein Response